Houry Leblebjian

542 total citations
31 papers, 224 citations indexed

About

Houry Leblebjian is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Houry Leblebjian has authored 31 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 11 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Houry Leblebjian's work include Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Houry Leblebjian is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Houry Leblebjian collaborates with scholars based in United States, Australia and Italy. Houry Leblebjian's co-authors include Irene M. Ghobrial, Steven P. Treon, Aldo M. Roccaro, Francisco M. Marty, Lindsey R. Baden, Jacob P. Laubach, Robert J. Soiffer, Edie Weller, Ranjit Banwait and Nicolas C. Issa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Houry Leblebjian

29 papers receiving 221 citations

Peers

Houry Leblebjian

GENET

HEMAT

PFM

IMMUN

Shin Young Hyun South Korea

Michelle Mahler United States

Sara Miqueleiz Italy

Elena Tagliaferri Italy

Victoria R. Alegria United States

Estelle Guérin France

Achille Aouba France

Alicia Bailén Spain

M J Grange France

Anna Waszczuk‐Gajda Poland

Shin Young Hyun South Korea

Houry Leblebjian

52 ×0.5

GENET

125 ×1.4

HEMAT

44 ×0.6

PFM

41 ×0.8

65 ×1.4

IMMUN

Citations per year, relative to Houry Leblebjian Houry Leblebjian (= 1×) peers Shin Young Hyun

Countries citing papers authored by Houry Leblebjian

Since Specialization

Citations

This map shows the geographic impact of Houry Leblebjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Houry Leblebjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Houry Leblebjian more than expected).

Fields of papers citing papers by Houry Leblebjian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Houry Leblebjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Houry Leblebjian. The network helps show where Houry Leblebjian may publish in the future.

Co-authorship network of co-authors of Houry Leblebjian

This figure shows the co-authorship network connecting the top 25 collaborators of Houry Leblebjian. A scholar is included among the top collaborators of Houry Leblebjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Houry Leblebjian. Houry Leblebjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leblebjian, Houry, et al.. (2025). The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies. Journal of Oncology Pharmacy Practice. 3222431484–3222431484.

Mo, Clifton C., Houry Leblebjian, Eileen Regan, et al.. (2025). Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma. European Journal Of Haematology. 114(6). 982–989. 1 indexed citations

Liacos, Christine‐Ivy, Foteini Theodorakakou, Despina Fotiou, et al.. (2023). Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer Journal. 13(1). 31–31. 13 indexed citations

Pandya, Chintan, et al.. (2022). Outcomes of Immune Checkpoint Inhibitor Administration in Hospitalized Patients With Solid Tumor Malignancies. JCO Oncology Practice. 19(2). e298–e305. 6 indexed citations

McDonnell, Anne, et al.. (2021). Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib. Leukemia Research. 108. 106610–106610. 2 indexed citations

Kotwal, Anupam, Yee-Ming Melody Cheung, Andjela Drincic, et al.. (2021). Patient-Centered Diabetes Care of Cancer Patients. Current Diabetes Reports. 21(12). 62–62. 8 indexed citations

Nadeem, Omar, Robert Redd, Alexandra Savell, et al.. (2021). A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood. 138(Supplement 1). 2749–2749. 5 indexed citations

Parnes, Aric, et al.. (2021). Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. Journal of Oncology Pharmacy Practice. 28(2). 421–424. 3 indexed citations

Munshi, Nikhil C., et al.. (2021). Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma. Blood. 138(Supplement 1). 666–666. 1 indexed citations

10.

Munshi, Nikhil C., et al.. (2020). Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD). Blood. 136(Supplement 1). 11–11.

11.

Leblebjian, Houry, Brett Glotzbecker, Mark M. Awad, et al.. (2019). Outcomes of immunotherapy administration for hospitalized cancer patients.. Journal of Clinical Oncology. 37(15_suppl). e18225–e18225. 1 indexed citations

12.

Leblebjian, Houry & Aric Parnes. (2017). Direct Oral Anticoagulants in Anti-Phospholipid Syndrome. Blood. 130. 2145–2145. 1 indexed citations

13.

Ghobrial, Irene M., Robert Redd, Philippe Armand, et al.. (2015). Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 29(12). 2338–2346. 26 indexed citations

14.

Şahin, İlyas, Houry Leblebjian, Steven P. Treon, & Irene M. Ghobrial. (2014). Waldenström macroglobulinemia: from biology to treatment. Expert Review of Hematology. 7(1). 157–168. 12 indexed citations

15.

Ghobrial, Irene M., Jacob P. Laubach, Kenneth H. Shain, et al.. (2014). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 124(21). 5777–5777. 3 indexed citations

16.

Leblebjian, Houry, Daniel J. DeAngelo, Richard M. Stone, et al.. (2013). Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leukemia Research. 37(7). 747–751. 15 indexed citations

17.

Issa, Nicolas C., Francisco M. Marty, Houry Leblebjian, et al.. (2013). Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation. 20(2). 285–287. 42 indexed citations

18.

Leblebjian, Houry, Amit Agarwal, & Irene M. Ghobrial. (2013). Novel Treatment Options for Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma & Leukemia. 13. S310–S316. 7 indexed citations

19.

Ghobrial, Irene M., Kenneth H. Shain, Ranjit Banwait, et al.. (2013). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. Blood. 122(21). 1947–1947. 3 indexed citations

20.

Leblebjian, Houry, Anne McDonnell, Martha Wadleigh, et al.. (2010). Predictive Factors for All-Trans Retinoic Acid Related Differentiation Syndrome In Acute Promyelocytic Leukemia.. Blood. 116(21). 1052–1052. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact